Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharming Group N V ADS each representing 10 Ord Shs PHAR

Healthcare Biotechnology
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.


NDAQ:PHAR - Post by User

Pharming Group N V ADS each representing 10 Ord Shs
<< Previous
 Bullboard Posts
User Avatar Image
(14)
•••
Post by khandaanita4444on Feb 09, 2024 11:21am
27 Views
Post# 35872388

$IBGR: Premier Penny Stock with High Volume.

$IBGR: Premier Penny Stock with High Volume.

In the OTC market, $IBGR stands out brightly! With an impressive 30-day average volume of 934,610K shares, it emerges as the premier penny stock choice for investors looking to capitalize on growth opportunities and access enhanced market liquidity. Positioned as a top contender, IBGR offers investors a promising avenue to navigate the dynamic landscape of penny stocks with confidence.

 

https://finance.yahoo.com/quote/IBGR?p=IBGR

 
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities